TATA-box binding protein associated factor, RNA polymerase I subunit DGenealiases: JOSD3 · RAFI41 · TAF(I)41 · TAFI41
Q-omics provides the consensus-scored TAF1D profile across patient tissues and cancer cell-line models. TAF1D expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TAF1D is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TAF1D RNA expression shows 19,574 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where TAF1D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF1D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF1D survival associations across molecular data types. TAF1D RNA expression shows survival associations in the most cancer types (30), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF1D RNA expression–survival associations across cancer types. High TAF1D expression shows unfavorable associations in ACC, KIRP, LIHC, KICH and BLCA, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TAF1D RNA expression.
This table summarizes TAF1D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TAF1D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF1D shows higher tumor expression in KIRC, HNSC, COAD, LIHC, LUAD and STAD. The KIRC box plot shows higher TAF1D RNA expression in tumor versus normal tissue (log2 FC = +1.416, t-test p < 0.001).
This table shows molecular features associated with TAF1D in patient tissues and cancer cell lines. In patient samples, TAF1D shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TAF1D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
